Anti-angiogenesis in cancer therapy.
OBJECTIVE
To review tumor angiogenesis, identify potential targets for anti-angiogenic cancer therapy, and highlight certain anti-angiogenic agents in clinical trials.


METHODS
Research articles, abstracts, review articles, and book chapters.


CONCLUSIONS
Tumor angiogenesis is a complex, multistep process that provides a target for antineoplastic therapy whereby tumor neovasculature is interrupted at various steps in the angiogenic process. Clinical trials are investigating the application and efficacy of anti-angiogenic agents.


CONCLUSIONS
Oncology nurses must continually increase their knowledge with the onset of newer, targeted agents. This will provide a background for educating and caring for the patient who is receiving anti-angiogenic therapy.
Muehlbauer
Paula M
PM
Clinical Center Nursing Department, National Institutes of Health, Bethesda, MD, USA.
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000276:immunology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology; D008222:Lymphokines / Q000276:immunology; D009369:Neoplasms / Q000098:blood supply / Q000451:nursing* / Q000628:therapy; D009859:Oncology Nursing; D013792:Thalidomide / Q000008:administration & dosage / Q000494:pharmacology; D014020:Tissue Extracts / Q000008:administration & dosage / Q000494:pharmacology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D036341:Intercellular Signaling Peptides and Proteins; D016898:Interferon-alpha; D008222:Lymphokines; D014020:Tissue Extracts; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C111481:shark cartilage extract; D013792:Thalidomide; C100342:marimastat